AKERO THERAPEUTICS INC(NASDAQ:AKRO) stock News

AKRO Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Chartmill

Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism

4 days ago - By: Zacks Investment Research - Mentions: AMRN RCKT ALGS

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

11 days ago - By: Akero Therapeutics Inc.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

11 days ago - By: Akero Therapeutics Inc.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

11 days ago - By: Zacks Investment Research - Mentions: ALLO AMRN ALGS

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

13 days ago - By: Zacks Investment Research - Mentions: AVAH

Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?

17 days ago - By: The Motley Fool

Akero (AKRO) Q2 Loss Narrows 6%

17 days ago - By: Akero Therapeutics Inc.

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

17 days ago - By: Akero Therapeutics Inc.

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

21 days ago - By: Benzinga - Mentions: AVAV AIV WRD WVE ...

This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

a month ago - By: Zacks Investment Research - Mentions: SNY APLS ARVN

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

3 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

3 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

3 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

3 months ago - By: Benzinga - Mentions: BMY BSX HUM LLY ...

10 Health Care Stocks With Whale Alerts In Today's Session

3 months ago - By: MarketBeat - Mentions: REGN VRTX XBI

Best Biotech Stocks to Buy in 2025

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Yahoo Finance

Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now

4 months ago - By: Yahoo Finance - Mentions: DDOG BCS GS DHI ...

3 Reasons Datadog Stock Is Still a Top Artificial Intelligence Buy Right Now

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH),

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

4 months ago - By: Akero Therapeutics Inc.

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

4 months ago - By: Grabar Law Office - Mentions: IART MRCY VIRT

Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office

AKERO THERAPEUTICS INC (AKRO) Stock News

AKRO Latest News, Press Relases and Analysis